The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|April 25, 2018
GRAM Adds Vial Filling Line
Author(s)Pharmaceutical Technology Editors
Grand River Aseptic Manufacturing announces equipment purchase to add vial filling capacity.
Advertisement
Grand River Aseptic Manufacturing, Inc. (GRAM), a parenteral contract development and manufacturing organization, announced on April 24, 2018 the purchase of a Bausch+Ströbel high-speed filling line with SKAN isolator, marking the second major equipment purchase of the year. In March 2018, the company previously announced the purchase of a new syringe filler and a land purchase agreement to acquire a 1.5-acre lot in Grand Rapids, MI.
The filling line can fill 200 vials per minute, which will more than triple the company’s manufacturing capacity, according to a press statement. The integrated fill line includes a vial washer, depyrogenation tunnel, and filling machine and the capacity to fill vials ranging from 2mL–50mL with 100% weight checks.
The company noted that it is reinvesting in the development of clinical-scale manufacturing.
Source:
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
Advertisement
Advertisement